- Each arm of the business is expected to post revenue growth this year
- The shares are trading at 10 times forward earnings
It can be difficult for a company to know exactly when to give up on an underperforming division and attempt to find a willing buyer. Management at Hikma Pharmaceuticals (HIK) is no doubt asking itself some difficult questions about the fate of the company’s generic medicines arm after a tricky 2022.